Evaluate the safety and explore the biological effects of different dosages of rhNGF
Typical Retinitis Pigmentosa
Drug: rhNGF 60 µg/ml eye drops solution
Drug: rhNGF 180 µg/ml eye drops solution
The primary objective of the study is to assess the safety and tolerability of two dose regimens of recombinant human nerve growth factor (rhNGF) eye drops solution administered over 6 months versus a vehicle control in patients with typical retinitis pigmentosa.
The secondary objective of this study is to attempt to show a dose response by assessing the potential efficacy of the rhNGF dose regimens for improving or slowing the deterioration of visual function outcomes at 3 and 6 months. During a 6 month follow-up period patients will be monitored to determine if there is evidence of a persistent biological effect after discontinuation of the study treatment.
Copyright 2017 © Dompé farmaceutici S.p.A. All rights reserved.
Dompè does not assume any responsibility for the contents